DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models
Journal of Clinical Investigation · 15.05.2024 · 134 (10)
DOI: 10.1172/jci172716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.03.2024. Verfasst von Zhen Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Aniline Compounds, ErbB Receptors. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Emory University.
Abstract (Originalsprache)
Development of effective strategies to manage the inevitable acquired resistance to osimertinib, a third-generation EGFR inhibitor for the treatment of EGFR-mutant (EGFRm) non–small cell lung cancer (NSCLC), is urgently needed. This study reports that DNA topoisomerase II (Topo II) inhibitors, doxorubicin and etoposide, synergistically decreased cell survival, with enhanced induction of DNA damage and apoptosis in osimertinib-resistant cells; suppressed the growth of osimertinib-resistant tumors; and delayed the emergence of osimertinib-acquired resistance. Mechanistically, osimertinib decreased Topo IIα levels in EGFRm NSCLC cells by facilitating FBXW7-mediated proteasomal degradation, resulting in induction of DNA damage; these effects were lost in osimertinib-resistant cell lines that possess elevated levels of Topo IIα. Increased Topo IIα levels were also detected in the majority of tissue samples from patients with NSCLC after relapse from EGFR tyrosine kinase inhibitor treatment. Enforced expression of an ectopic TOP2A gene in sensitive EGFRm NSCLC cells conferred resistance to osimertinib, whereas knockdown of TOP2A in osimertinib-resistant cell lines restored their susceptibility to osimertinib-induced DNA damage and apoptosis. Together, these results reveal an essential role of Topo IIα inhibition in mediating the therapeutic efficacy of osimertinib against EGFRm NSCLC, providing scientific rationale for targeting Topo II to manage acquired resistance to osimertinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA.
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Förderung
- NCI NIH HHS
- National Institutes of Health
- Emory University
Zitieren
APA
Chen, Z., Vallega, K. A., Wang, D., Quan, Z., Fan, S., Wang, Q., Leal, T., Ramalingam, S. S., & Sun, S. Y. (2024). DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models. Journal of Clinical Investigation, 134(10). https://doi.org/10.1172/jci172716
Vancouver
Chen Z, Vallega KA, Wang D, Quan Z, Fan S, Wang Q, et al. DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models. Journal of Clinical Investigation. 2024;134(10). doi:10.1172/jci172716
BibTeX
@article{Chen2024,
author = {Chen, Zhen and Vallega, Karin A and Wang, Dongsheng and Quan, Zihan and Fan, Songqing and Wang, Qiming and Leal, Ticiana and Ramalingam, Suresh S and Sun, Shi-Yong},
title = {DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {10},
doi = {10.1172/jci172716}
}
EUVIMED